Show Summary Details
Page of

Optimal medical therapy in percutaneous coronary intervention patients: statins and ACE inhibitors as disease-modifying agents 

Optimal medical therapy in percutaneous coronary intervention patients: statins and ACE inhibitors as disease-modifying agents
Chapter:
Optimal medical therapy in percutaneous coronary intervention patients: statins and ACE inhibitors as disease-modifying agents
Author(s):

Simon J. Corbett

, and Kim F. Fox

DOI:
10.1093/med/9780199569083.003.026
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 01 December 2020

The majority of this textbook is concerned with the indications for, and applications of, the numerous techniques that interventional cardiologists have at their disposal to assess and treat significant coronary stenoses. However, it is well recognized that atherosclerosis is far from being a discrete pathological process, such that by the time a person presents with clinically apparent coronary artery disease (CAD), they will often have widespread atheroma throughout their coronary tree. Combined with the reproducible observation that the majority of acute coronary syndromes arise from lesions that were not previously flow-limiting, much research effort has been directed at identifying treatment strategies that will favourably modify all of the patient’s atherosclerotic burden, not just that which can be targeted by percutaneous or surgical revascularization. In this chapter, we focus on the rationale and evidence base supporting the use of statins and renin–angiotensin–aldosterone system (RAAS) inhibition in patients with CAD.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.